This Map17 antibody is useful for Western blot, where a major band of ~14 kDa is detected. Minor cross-reacting bands are visible at higher molecular weights. This antibody is not applicable for ICC/IF.
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
14 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publication using NB400-151 in the following applications:
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
0.05% Sodium Azide
Alternate Names for Map17 Antibody
17 kDa membrane-associated protein
MAP17epithelial protein up-regulated in carcinoma, membrane associated protein 17
membrane-associated protein 17
PDZK1 interacting protein 1
PDZK1-interacting protein 1
MAP17 (17 kD membrane-associated protein) is a small non-glycosylated protein which localize to plasma membrane as well as Golgi apparatus, and interacts with several PDZ domain-containing proteins such as NHeRF proteins, NaPi-IIa, and NHe3. Overexpression of MAP17 in OK cells (opossum kidney epithelial cells) participates in NaPi-IIa internalization to the trans-Golgi network. In mouse, MAP17 overexpression in liver resulted in PDZK1 (NHeRF3) hepatic deficiency, suggesting MAP17's role in endogenous regulation of PDZK1 turnover. MAP17 acts as an atypical anchoring site for PDZK1 and interacts with NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells, wherein its physiological role is not well known, but it does stimulate specific Na-dependent transport of mannose and glucose in Xenopus oocytes as well as in human cancer cells. MAP17 is overexpressed in a variety of human carcinomas and its overexpression strongly correlates with ROS overproduction as well as tumoral progression characterized by decreased apoptotic sensitivity with enhanced proliferation and migration in prostate, breast, ovarian cancer etc. This increase in ROS as well as tumor aggressiveness relies largely on its PDZ-binding domain as disruption of this sequence by point mutations has been shown to abolish MAP17's ability to enhance ROS production and tumorigenesis.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Map17 Antibody and receive a gift card or discount.